Pharmbio Korea signs exclusive license agreement of new opioid painkiller with U.S.

Published: 2018-05-15 22:12:34

Updated: 2018-05-15 22:12:34

Pharmbio Korea(Chairman Bong-Gil Nam) announced on the 14^th that the company signed an exclusive license agreement for development and commercialization of Oliceridine, an opioid, intravenous injection being developed, in the Korean market with Trevana, a U.S. biopharmaceutical company.

Oliceridine is an innovative new drug which was created to effectively reduce moderate and severe acute pain...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.